Caris Precision Oncology Alliance Hosts Georgia Cancer Center at Augusta University


The Georgia Cancer Center seamlessly combines high-quality clinical care with translational research in its role as the cancer center for the State Academic Medical Center at the University of Augusta.

IRVING, Texas, November 11, 2021 / PRNewswire / – Caris Life Sciences® (Caris), the leading molecular science and technology company that actively develops and delivers innovative solutions to revolutionize healthcare, today announced that the Georgia Cancer Center at Augusta The university has joined the Caris Precision Oncology Alliance â„¢ (POA). POA is a growing network of leading cancer centers around the world collaborating to advance precision oncology and biomarker-driven research. POA members work together to set and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve clinical outcomes for cancer patients.

Caris Life Sciences logo (PRNewsfoto / Caris Life Sciences)

The Georgia Cancer Center has a long history of offering clinical trials, including therapies developed in its own laboratories, to both adults and children with all types of cancer. Its relationship with the National Cancer Institute (NCI) community oncology research programs began in 1994 with a predecessor, the Minority-Based Community Clinical Oncology Program, or MBCCOP. Today, the Georgia Cancer Center continues to lead the state’s only minority-based research program through NCI’s NCORP.

“We are delighted to collaborate with other leading research and innovation-driven institutions through the Caris Precision Oncology Alliance,” said Jorge E. Cortés, MD, director, Georgia Cancer Center. “We are convinced that through clinical and translational research, we are not only providing the best patient care, but we are driving the improvements needed in the diagnosis, prevention and treatment of cancer, now and in the future. . “

The Georgia Cancer Center is on track to earn the National Cancer Institute designation through the NCI Cancer Centers Support Grants program, which seeks to become the state’s second institution to do it. By definition, an NCI-designated cancer center is a nationally recognized leader in cancer research, which includes clinical trials.

“The Georgia Cancer Center’s multidisciplinary approach to cancer care allows their physicians and researchers to focus on promoting innovation to improve patient outcomes,” said Chadi Nabhan, MD, MBA, FACP, President of the Caris Precision Oncology Alliance. “The POA is excited to work with partners like the Georgia Cancer Center who are supporting the elimination of the threat of cancer by providing all members of their community with access to high quality, research-based cancer care. The clinical research talent at the Georgia Cancer Center complements the POA’s strategic vision and mission statements, and is intended to enhance ongoing research capabilities. “

“The Georgia Cancer Center at Augusta The university offers the most advanced cancer care in the region, ”said Brian J. Brille, vice-president of Caris Life Sciences. “Their team of top oncology physicians and researchers are able to support patients and their families with the latest cutting-edge treatment options in precision medicine, and the POA praises their expertise in the field. “

Serve a dozen Georgia counties, the Georgia Cancer Center provides comprehensive care for children and adults using a patient-centered model, which emphasizes the best available treatments as well as a wide range of supportive services, including integrative medicine. . It also includes multidisciplinary tumor committees, research units dedicated to clinical trials, pivot nurses, on-site fusion services, radiation oncology, and blood and bone marrow transplantation, as well as medical services. surgical and medical oncology with the largest team of oncologists in the region.

The Caris Precision Oncology Alliance includes 55 cancer centers and academic institutions. These institutions have quick access to Caris’ extensive database and artificial intelligence platform to set evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through the Caris Molecular Intelligence® platform, Caris seeks to provide this network with the ability to prioritize treatment options and determine what clinical trial opportunities may benefit their patients. . POA members are also able to fit into a growing portfolio of biopharma sponsored biomarker directed trials. Additionally, as a member of the POA, institutions have access to Caris CODEai â„¢, the industry’s most comprehensive data solution with cancer treatment information and clinical outcome data for over 275,000 patients. covering over 1,000,000 data points per patient.

About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris created the large-scale clinico-genomic database and cognitive computing necessary to analyze and unravel the molecular complexity of disease. This information is an unparalleled resource and the ideal avenue for conducting basic and basic research to accelerate discovery for the detection, diagnosis, monitoring, selection of therapies and development of drugs to improve the human condition.

With a primary focus on cancer, Caris’ industry-leading molecular profiling suite of offerings assesses DNA, RNA, and proteins to reveal a molecular pattern that helps patients, physicians, and researchers better detect , diagnose and treat patients. Caris’ latest advancement, which is currently available within its Precision Oncology Alliance, is a blood-based circulating nucleic acid sequencing (cNAS) assay that combines full molecular analysis (whole exome and transcriptome sequencing). whole from blood) and serial monitoring – making this the most powerful liquid biopsy test ever developed.

Based at Irving, Texas, Caris has offices in Phoenix, New York, Denver and Basel, Switzerland. Caris provides services across the United States, Europe, Asia and other international markets. To find out more, please visit CarisLifeSciences.com or follow us on Twitter (@CarisLS).

About the Georgia Cancer Center at Augusta University
The Georgia Cancer Center at Augusta The University is dedicated to reducing the burden of cancer in Georgia and across the world through superior care, innovation and education. Through unprecedented expansion, Georgia Cancer Center is providing access to more top-notch clinical trials, world-renowned experts, and life-saving options. For more information, please visit Augusta.edu/Cancer.

Caris Life Sciences press contact:
Allison kreutzjans
Edelman
[email protected]
314-550-1327

The Georgia Cancer Center at Augusta Univ Media Contact:
Chris curry
Communication and Marketing Manager
[email protected]
706-799-8841

Cision

Cision

View original content to download multimedia: https://www.prnewswire.com/news-releases/caris-precision-oncology-alliance-welcomes-the-georgia-cancer-center-at-augusta-university-301421959.html

SOURCE Caris Life Sciences



Comments are closed.